{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:39:12Z","timestamp":1778128752117,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijpharm.2018.08.047","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T22:47:35Z","timestamp":1535150855000},"page":"278-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeted efflux transporter inhibitors \u2013 A solution to improve poor cellular accumulation of anti-cancer agents"],"prefix":"10.1016","volume":"550","author":[{"given":"Johanna","family":"Huttunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Gynther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina M.","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2018.08.047_b0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.clpt.6100104","article-title":"Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice","volume":"81","author":"Bailey","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0010","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1073\/pnas.96.21.12079","article-title":"Selective expression of the large neutral amino acid transporter at the blood-brain barrier","volume":"96","author":"Boado","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/glia.21116","article-title":"Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells","volume":"59","author":"Braun","year":"2011","journal-title":"Glia"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.113.056176","article-title":"Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?","volume":"42","author":"Callaghan","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","author":"Cascorbi","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0030","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1074\/jbc.M110.166868","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation","volume":"286","author":"Copsel","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0035","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-15-3376","article-title":"Genetic disruption of the multifunctional CD98\/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth","volume":"76","author":"Cormerais","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0040","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/mp300570z","article-title":"Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states","volume":"10","author":"Deo","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0045","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bcp.2010.05.021","article-title":"Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors","volume":"80","author":"Fan","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbrc.2013.08.020","article-title":"A new treatment for human malignant melanoma targeting l-type amino acid transporter 1 (LAT1): a pilot study in a canine model","volume":"439","author":"Fukumoto","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12958-015-0054-8","article-title":"Expression and functional characterisation of System L amino acid transporters in the human term placenta","volume":"13","author":"Gaccioli","year":"2015","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/jpet.102.035014","article-title":"Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition","volume":"302","author":"Gerk","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.31887\/DCNS.2006.8.3\/fgirardin","article-title":"Membrane transporter proteins: a challenge for CNS drug development","volume":"8","author":"Girardin","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0080","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s11064-016-1996-8","article-title":"Amino acid promoieties alter valproic acid pharmacokinetics and enable extended brain exposure","volume":"41","author":"Gynther","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0085","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.4049\/jimmunol.1300923","article-title":"LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells","volume":"191","author":"Hayashi","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0090","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.bjp.0706008","article-title":"Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux","volume":"143","author":"Honda","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0095","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1021\/acs.jmedchem.6b00190","article-title":"A selective and slowly reversible inhibitor of l-type amino acid transporter 1 (LAT1) potentiates antiproliferative drug efficacy in cancer cells","volume":"59","author":"Huttunen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2015.12.034","article-title":"l-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors","volume":"498","author":"Huttunen","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0105","first-page":"4819","article-title":"Inhibition of l-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer","volume":"30","author":"Imai","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1248\/bpb.b16-00970","article-title":"Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs","volume":"40","author":"Iwaki","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0115","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkm353","article-title":"Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes","volume":"60","author":"Janneh","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy","author":"Keppler","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/bbrc.2001.4746","article-title":"Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid","volume":"283","author":"Kim","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2014.05.001","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) regulates thrombus formation in vitro and in vivo","volume":"737","author":"Lien","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2014.04.004","article-title":"Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans","volume":"59","author":"Maeda","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s11095-009-9890-6","article-title":"Efflux protein expression in human retinal pigment epithelium cell lines","volume":"26","author":"Mannermaa","year":"2009","journal-title":"Pharm Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0160","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/ijc.30371","article-title":"LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma","volume":"139","author":"Marshall","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-642-14541-4_9","article-title":"In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP\/MXR\/ABCP\/ABCG2)","author":"Meyer zu Schwabedissen","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0170","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1248\/bpb.b16-00319","article-title":"Screening to identify multidrug resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity","volume":"39","author":"Nakamichi","year":"2016","journal-title":"Biol. Pharm. Bull"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/(SICI)1097-0215(19960301)65:5<613::AID-IJC10>3.0.CO;2-8","article-title":"Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate","volume":"65","author":"Norris","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0185","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s11095-012-0966-3","article-title":"Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine","volume":"30","author":"Peura","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0190","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/mp2001878","article-title":"Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery","volume":"8","author":"Peura","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0195","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/bbrc.1999.0206","article-title":"Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function","volume":"255","author":"Prasad","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0200","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","article-title":"The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites","volume":"4","author":"Pratt","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2017.06.023","article-title":"l-type amino acid transporter 1 utilizing prodrugs: how to achieve effective brain delivery and low systemic exposure of drugs","volume":"261","author":"Puris","year":"2017","journal-title":"J. Control Release"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0210","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/leu.2014.338","article-title":"l-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma\/T-cell acute lymphoblastic leukemia","volume":"29","author":"Rosilio","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0215","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/jps.22586","article-title":"Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and\/or P-glycoprotein","volume":"100","author":"Shirasaka","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bcp.2016.02.020","article-title":"Aryl hydrocarbon receptor (AHR) regulation of l-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells","volume":"106","author":"Tomblin","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0225","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0026-895X(24)12322-X","article-title":"Transport of amino acid-related compounds mediated by l-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition","volume":"61","author":"Uchino","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0230","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.106.012765","article-title":"Inhibition of MRP1\/ABCC1, MRP2\/ABCC2, and MRP3\/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors","volume":"35","author":"Weiss","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0235","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.juro.2015.11.071","article-title":"Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells","volume":"195","author":"Xu","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0240","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","article-title":"Renal drug transporters and their significance in drug-drug interactions","volume":"6","author":"Yin","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0245","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cmdc.201402281","article-title":"Quantitative insight into the design of compounds recognized by the l-type amino acid transporter 1 (LAT1)","volume":"9","author":"Ylikangas","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijpharm.2018.08.047_b0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-012-0986-1","article-title":"The role of LAT1 in (18)F-DOPA uptake in malignant gliomas","volume":"111","author":"Youland","year":"2013","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0255","first-page":"7225","article-title":"Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport","volume":"61","author":"Zeng","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2018.08.047_b0260","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug Resistance Proteins (MRPs) and Cancer Therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"Aaps J."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318306252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318306252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:37:19Z","timestamp":1759916239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517318306252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":52,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0378517318306252"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.08.047","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted efflux transporter inhibitors \u2013 A solution to improve poor cellular accumulation of anti-cancer agents","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}